Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biofrontera Inc (NQ: BFRI )

0.8940 +0.0139 (+1.58%)
Streaming Delayed Price Updated: 2:26 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,471
Open 0.8801
Bid (Size) 0.8750 (7)
Ask (Size) 0.8949 (1)
Prev. Close 0.8801
Today's Range 0.8600 - 0.9000
52wk Range 0.7501 - 6.120
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga

Performance

YTD
+5.79%
+5.79%
1 Month
-0.67%
-0.67%
3 Month
-10.60%
-10.60%
6 Month
-38.34%
-38.34%
1 Year
-79.82%
-79.82%

More News

Read More
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
Via ACCESSWIRE
Biofrontera's Return On Capital Employed Overview
Via Benzinga
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
From Biofrontera Inc.
Via Globe NewsWire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
From Biofrontera Inc.
Via Globe NewsWire
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket
Via Benzinga
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
From Biofrontera Inc.
Via Globe NewsWire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
From Biofrontera Inc.
Via Globe NewsWire
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
From Biofrontera Inc.
Via Globe NewsWire
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand
Via FinancialNewsMedia
Topics Death Economy
Exposures Death Economy
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
From Biofrontera Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Biofrontera's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.